Bolt Biotherapeutics (BOLT)
(Delayed Data from NSDQ)
$0.73 USD
0.00 (0.00%)
Updated Jul 24, 2024 03:46 PM ET
After-Market: $0.74 +0.01 (1.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Bolt Biotherapeutics, Inc. [BOLT]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Lead Product Development Discontinued; 50% Workforce Reduction
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Trastuzumab Imbotolimod (BDC-1001) Phase 2 Data and First BDC-3042 Data Anticipated in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 2 Trial of BDC-1001 in Patients With HER2-Positive Breast Cancer Following Enhertu
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Initial Phase 2 BDC-1001 Data Expected Next Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Update For BDC-1001 Presented at ESMO 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1/2 Study of BDC-3042
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Grants Orphan Drug Designation to BDC-1001 For the Treatment of Gastric Cancers
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; First Patients Dosed in Phase 2 Study of BDC-1001
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patients Dosed in Phase 2 Dose-Expansion Trial of BDC-1001 in HER2-Positive Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BDC-1001 Phase 1 Data in 131 Patients Presented at ASCO; Phase 2 Studies Underway in Four Tumor Types
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Monotherapy and Combination Data Presented in ASCO Abstract For BDC-1001
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Full Phase 1 BDC-1001 Data at ASCO; BDC-3042 Could Enter the Clinic This Fall
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Positive Top-Line Phase 1 Dose Escalation Results For BDC-1001 Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; BDC-1001 Phase 1/2 Topline Data and RP2D Expected 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
This Immuno-Oncology Company Could Spark Investor Interest; Initiate With Buy Rating and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Bolt Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Bolt Biotherapeutics, Inc.
Industry: Oil and Gas - Mechanical and and Equipment
Dropping coverage due to weaker than expected performance.
Provider: SINGULAR RESEARCH
Analyst: GARNER G
|